Multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, and dementia with Lewy bodies are among the Parkinsonian disorders, which include idiopathic Parkinson’s disease (PD) and atypical Parkinsonian disorders (APD), such as multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, and dementia with Lewy bodies. Although the exact cause of these illnesses is unknown, it is thought to be a combination of hereditary and environmental factors. The lack of biomarkers is one of the most significant barriers to creating effective disease-modifying therapy options. Early and precise diagnosis, measurement of disease progression, and response to therapy all require reliable biomarkers. Alpha-synuclein, which appears to be integrally involved in the aetiology of synucleinopathies and whose levels can be detected in the cerebrospinal fluid and plasma, is one of the most promising CSF biomarker possibilities. Tau protein build-up appears to have a role in the aetiology of tauopathies in a similar fashion. Urate, a powerful antioxidant, appears to be linked to the likelihood of developing PD and the course of the disease. In APD, levels of neurofilament light chains are higher than in PD and healthy individuals.